NCT06869278View on ClinicalTrials.gov

A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases

PHASE1RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

June 17, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2029

Conditions
Multiple Sclerosis (MS)Neuromyelitis Optica Spectrum Disease (NMOSD)Anti-Myelin Oligodendrocyte Glycoprotein-IgG Associated Disorders (MOGAD)Myasthenia Gravis
Interventions
BIOLOGICAL

LCAR-AIO T cells

Before treatment with LCAR-AIO T cells, subjects will receive a conditioning regimen.

Trial Locations (3)

Unknown

NOT_YET_RECRUITING

The Affiliated Hospital of Fujian Medical University, Fuzhou

RECRUITING

The First Affiliated Hospital of SOOCHOW University, Suzhou

RECRUITING

Union Hospital Tongji Medical College HUAZHONG University of Science and Technology, Wuhan

Sponsors
All Listed Sponsors
collaborator

Nanjing Legend Biotech Co.

INDUSTRY

lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER

NCT06869278 - A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases | Biotech Hunter | Biotech Hunter